NovaBay Issues Statement Regarding Market Activity
29 févr. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective...
NovaBay Pharmaceuticals Provides Business Update and 2012 Outlook
09 févr. 2012 08h00 HE
|
NovaBay Pharmaceuticals, Inc.
Progress Across Four Business Units
Conference Call and Webcast Today at 1:00 P.M. (ET) / 10:00 A.M. (PT)
Dial-In Numbers
1-866-761-0748 (USA) or 1-617-614-2706 (International)
Participant...
NovaBay Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
08 févr. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 8, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective...
NovaBay Pharmaceuticals to Hold Conference Call to Provide Year-End Business Update and 2012 Outlook
07 févr. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 7, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective...
NovaBay Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422
23 janv. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
Selects Top Contract Research Organizations to Manage Clinical Trial
Study to Enroll Patients With Confirmed Adenoviral Conjunctivitis in India, Brazil and U.S.
EMERYVILLE, Calif., Jan. 23,...
NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China
09 janv. 2012 09h06 HE
|
NovaBay Pharmaceuticals, Inc.
NovaBay to Receive Up to $1.3M in Upfront and Milestone Payments
Seeks Strategic Partners for Additional Global Territories
EMERYVILLE, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- NovaBay®...
NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program
30 nov. 2011 07h00 HE
|
NovaBay Pharmaceuticals, Inc.
Part B of Study With More Potent Formulation Currently Underway
EMERYVILLE, Calif., Nov. 30, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE AMEX:NBY), a clinical-stage...
NovaBay Pharmaceuticals' Aganocide Compound, NVC-422, Featured in Drugs of the Future
14 nov. 2011 07h00 HE
|
NovaBay Pharmaceuticals, Inc.
NVC-422 Called "Effective Alternative to Known Antimicrobial Compounds"
EMERYVILLE, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- A monograph on NovaBay's lead Aganocide® NVC-422 was recently...
NovaBay Pharmaceuticals Reports Third Quarter Financial Results
07 nov. 2011 08h30 HE
|
NovaBay Pharmaceuticals, Inc.
Programs in Dermatology, Urology, Ophthalmology and Wound Care Advancing
EMERYVILLE, Calif., Nov. 7, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage...
NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)
14 oct. 2011 07h00 HE
|
NovaBay Pharmaceuticals, Inc.
NeutroPhase is a FDA 510(k) cleared advanced wound care product addressing the un-met medical needs of the six-million-patient USA chronic wound care market
EMERYVILLE, Calif., Oct. 14, 2011...